Bellus soars on positive mid-stage readout for its Merck cough rival, despite a failure in atopic dermatitis

Do investors want the good news, or the bad news first? Bellus went with the good news, sharing that its chronic cough contender hit the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bel­lus soars on pos­i­tive mid-stage read­out for its Mer­ck cough ri­val, de­spite a fail­ure in atopic der­mati­tis